TY - JOUR
T1 - Subjects at risk of Parkinson’s disease in health checkup examinees
T2 - cross-sectional analysis of baseline data of the NaT-PROBE study
AU - Hattori, Makoto
AU - Tsuboi, Takashi
AU - Yokoi, Katsunori
AU - Tanaka, Yasuhiro
AU - Sato, Maki
AU - Suzuki, Keisuke
AU - Arahata, Yutaka
AU - Hori, Akihiro
AU - Kawashima, Motoshi
AU - Hirakawa, Akihiro
AU - Washimi, Yukihiko
AU - Watanabe, Hirohisa
AU - Katsuno, Masahisa
N1 - Funding Information:
This work was funded by The Research Funding for Longevity Sciences (Nos. 28–8 and 19–20) from National Center for Geriatrics and Gerontology (NCGG), Japan; grants from Japan Agency for Medical Research and Development (Nos. 19dk0207027h0004, 19lk0201101h0001, and 19dm0107155h0001); and a grant from the Naito Foundation. Dr. Katsuno is supported by JSPS KAKENHI Grant Number 17H04195, Alnylam Japan, Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Takeda Pharmaceutical Co. Ltd., Biogen Japan, UCB Japan, and Novartis Pharma K.K., and grants from Dainippon Sumitomo Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, and CSL Behring K.K. Dr. Suzuki is supported by the Research Funding for Longevity Sciences (Nos. 28-8 and 19-20) from National Center for Geriatrics and Gerontology (NCGG); and a grant from the Japan Foundation For Aging And Health. Dr. Hirakawa is supported by a JSPS KAKENHI Grant Number JP15K15948; grants from Japan Agency for Medical Research and Development (Nos. 19de017004h0001 and 19mk0101169h0001). Dr. Watanabe is supported by Otsuka Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., FP Pharmaceutical Corporation, Eisai Co. Ltd., Daiichi Sankyo Company Limited, and Novartis Pharma K.K., and grants from Otsuka Pharmaceutical Co. Ltd. and FUJIFILM RI Pharma Co. Ltd.
Funding Information:
The authors are grateful to all the participants in this study. Dr. Katsuno is supported by a JSPS KAKENHI Grant Number JP17H04195; grants from Japan Agency for Medical Research and Development (Nos. 19ek0109221h0003, 19ek0109359h0002, 19dk0207027h0004, 19lk0201101h0001, and 19dm0107155h0001); a grant from the Naito Foundation; and a grant from the Hori Sciences and Arts Foundation.
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Introduction: The present study aimed to survey the prevalence of prodromal symptoms of Parkinson’s disease (PD) in Japanese health checkup examinees, for identifying at-risk subjects. Methods: We conducted a questionnaire survey of annual health checkup examinees without neurological symptoms using the following self-reported questionnaires: Japanese version of the Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT); Self-administered Odor Question (SAOQ); REM Sleep Behavior Disorder Screening Scale (RBDSQ); Beck Depression Inventory-Second Edition (BDI-II); Epworth Sleepiness Scale (ESS); and Physical Activity Scale for the Elderly (PASE). The presence of prodromal symptoms was determined using the 90th percentile threshold of each questionnaire. Subjects ≥ 50 years of age with ≥ 2 core prodromal symptoms (dysautonomia, hyposmia, and RBD), were classified as at risk. Results: Between March 2017 and March 2018, 4,953 participants sufficiently answered the questionnaires. Among 2,726 subjects ≥ 50 years of age, 155 were classified as at risk. These subjects had worse values of BDI-II (12.0 ± 8.3 vs. 4.4 ± 3.8, p < 0.001) and ESS (9.6 ± 5.0 vs. 6.3 ± 3.2, p < 0.001), in addition to SCOPA-AUT, SAOQ, and RBDSQ. Male at-risk subjects showed lower values of hemoglobin (14.8 ± 1.3 vs. 15.0 ± 1.1, p = 0.032) and low density lipoprotein cholesterol (114.5 ± 30.3 vs. 123.0 ± 28.9, p = 0.004) than the examinees reporting no prodromal symptoms. Conclusion: Approximately 6% of the population aged 50 years or older was at risk for PD. Male at-risk subjects had mild hematological and metabolic changes relevant to PD.
AB - Introduction: The present study aimed to survey the prevalence of prodromal symptoms of Parkinson’s disease (PD) in Japanese health checkup examinees, for identifying at-risk subjects. Methods: We conducted a questionnaire survey of annual health checkup examinees without neurological symptoms using the following self-reported questionnaires: Japanese version of the Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT); Self-administered Odor Question (SAOQ); REM Sleep Behavior Disorder Screening Scale (RBDSQ); Beck Depression Inventory-Second Edition (BDI-II); Epworth Sleepiness Scale (ESS); and Physical Activity Scale for the Elderly (PASE). The presence of prodromal symptoms was determined using the 90th percentile threshold of each questionnaire. Subjects ≥ 50 years of age with ≥ 2 core prodromal symptoms (dysautonomia, hyposmia, and RBD), were classified as at risk. Results: Between March 2017 and March 2018, 4,953 participants sufficiently answered the questionnaires. Among 2,726 subjects ≥ 50 years of age, 155 were classified as at risk. These subjects had worse values of BDI-II (12.0 ± 8.3 vs. 4.4 ± 3.8, p < 0.001) and ESS (9.6 ± 5.0 vs. 6.3 ± 3.2, p < 0.001), in addition to SCOPA-AUT, SAOQ, and RBDSQ. Male at-risk subjects showed lower values of hemoglobin (14.8 ± 1.3 vs. 15.0 ± 1.1, p = 0.032) and low density lipoprotein cholesterol (114.5 ± 30.3 vs. 123.0 ± 28.9, p = 0.004) than the examinees reporting no prodromal symptoms. Conclusion: Approximately 6% of the population aged 50 years or older was at risk for PD. Male at-risk subjects had mild hematological and metabolic changes relevant to PD.
UR - http://www.scopus.com/inward/record.url?scp=85079505539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079505539&partnerID=8YFLogxK
U2 - 10.1007/s00415-020-09714-6
DO - 10.1007/s00415-020-09714-6
M3 - Article
C2 - 32030520
AN - SCOPUS:85079505539
VL - 267
SP - 1516
EP - 1526
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
IS - 5
ER -